Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
CAMBRIDGE, Mass., Oct. 06, 2016 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today the grant of an inducement award to the company’s newly appointed Chief Medical Officer, Gerald F. Cox, M.D., Ph.D. The award was approved by Editas’ Board of Directors on October 5, 2016 as an inducement material to Dr. Cox entering into employment with Editas, in accordance with NASDAQ Listing Rule 5635(c)(4).
The inducement grant to Dr. Cox consisted of an option to purchase up to 225,000 shares of common stock. The inducement grant is exercisable at a price of $15.48 per share, equal to the closing price per share of Editas’ common stock as reported by NASDAQ on October 5, 2016. The stock option vests over four years, with 25% of the shares vesting on October 3, 2017, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to Dr. Cox’s continued service relationship with Editas through the applicable vesting dates.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact: Mark Mullikin Editas Medicine, Inc. (617) 401-9083 [email protected]
